Ocular Therapeutix™ to Participate in Two Investor Conferences in April
Ocular Therapeutix (NASDAQ: OCUL), a biopharmaceutical company focused on retina treatments, has announced its participation in two major investor conferences this April. The first event is the 24th Annual Needham Virtual Healthcare Conference, where Dr. Pravin U. Dugel, Executive Chairman, President and CEO, will present on Monday, April 7, 2025, at 3:00 PM ET in a virtual format.
The second event is the Piper Sandler Spring Biopharma Symposium in Boston, MA, scheduled for Thursday, April 17, 2025, where the company will host one-on-one meetings with investors. Interested parties can access a live webcast of the Needham presentation through the Events and Presentations section of Ocular's Investor Relations webpage.
Ocular Therapeutix (NASDAQ: OCUL), un'azienda biofarmaceutica focalizzata sui trattamenti per la retina, ha annunciato la sua partecipazione a due importanti conferenze per investitori questo aprile. Il primo evento è il 24° Annual Needham Virtual Healthcare Conference, dove il Dr. Pravin U. Dugel, Presidente e CEO, presenterà lunedì 7 aprile 2025, alle 15:00 ET in formato virtuale.
Il secondo evento è il Piper Sandler Spring Biopharma Symposium a Boston, MA, previsto per giovedì 17 aprile 2025, dove l'azienda ospiterà incontri one-to-one con gli investitori. Le parti interessate possono accedere a una diretta web della presentazione di Needham attraverso la sezione Eventi e Presentazioni della pagina delle Relazioni con gli Investitori di Ocular.
Ocular Therapeutix (NASDAQ: OCUL), una empresa biofarmacéutica centrada en tratamientos para la retina, ha anunciado su participación en dos importantes conferencias para inversores este abril. El primer evento es la 24ª Conferencia Virtual de Salud de Needham, donde el Dr. Pravin U. Dugel, Presidente y CEO, presentará el lunes 7 de abril de 2025, a las 15:00 ET en formato virtual.
El segundo evento es el Simposio de Biopharma de Primavera de Piper Sandler en Boston, MA, programado para el jueves 17 de abril de 2025, donde la empresa llevará a cabo reuniones individuales con inversores. Las partes interesadas pueden acceder a una transmisión en vivo de la presentación de Needham a través de la sección de Eventos y Presentaciones de la página de Relaciones con Inversores de Ocular.
Ocular Therapeutix (NASDAQ: OCUL), 망막 치료에 중점을 둔 생명공학 회사가 이번 4월 두 개의 주요 투자자 회의에 참여한다고 발표했습니다. 첫 번째 행사는 2025년 4월 7일 월요일 오후 3시(동부 표준시)에 Dr. Pravin U. Dugel, 이사회 의장 겸 CEO가 가상 형식으로 발표할 24회 연례 Needham 가상 의료 회의입니다.
두 번째 행사는 2025년 4월 17일 목요일에 매사추세츠주 보스턴에서 열리는 Piper Sandler 봄 생명공학 심포지엄으로, 회사는 투자자와의 일대일 미팅을 주최할 예정입니다. 관심 있는 분들은 Ocular의 투자자 관계 웹페이지의 이벤트 및 발표 섹션을 통해 Needham 발표의 라이브 웹캐스트에 접속할 수 있습니다.
Ocular Therapeutix (NASDAQ: OCUL), une entreprise biopharmaceutique spécialisée dans les traitements de la rétine, a annoncé sa participation à deux grandes conférences d'investisseurs ce mois d'avril. Le premier événement est la 24e Conférence Virtuelle de Santé de Needham, où le Dr Pravin U. Dugel, Président et CEO, fera une présentation le lundi 7 avril 2025, à 15h00 ET, en format virtuel.
Le deuxième événement est le Symposium Printanier de Biopharma de Piper Sandler à Boston, MA, prévu pour le jeudi 17 avril 2025, où l'entreprise organisera des réunions individuelles avec des investisseurs. Les parties intéressées peuvent accéder à un webinaire en direct de la présentation de Needham via la section Événements et Présentations de la page des Relations avec les Investisseurs d'Ocular.
Ocular Therapeutix (NASDAQ: OCUL), ein biopharmazeutisches Unternehmen, das sich auf Retina-Behandlungen konzentriert, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im April angekündigt. Die erste Veranstaltung ist die 24. jährliche Needham Virtual Healthcare Conference, bei der Dr. Pravin U. Dugel, Vorstandsvorsitzender, Präsident und CEO, am Montag, den 7. April 2025, um 15:00 Uhr ET in virtueller Form präsentieren wird.
Die zweite Veranstaltung ist das Piper Sandler Spring Biopharma Symposium in Boston, MA, das für Donnerstag, den 17. April 2025, geplant ist, wo das Unternehmen Einzelgespräche mit Investoren führen wird. Interessierte Parteien können über den Bereich Veranstaltungen und Präsentationen auf der Investor Relations-Webseite von Ocular auf einen Live-Stream der Needham-Präsentation zugreifen.
- None.
- None.
BEDFORD, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in two investor conferences in April:
24th Annual Needham Virtual Healthcare Conference
Presentation Date: Monday, April 7, 2025
Presentation Time: 3:00 PM ET
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: Virtual
Piper Sandler Spring Biopharma Symposium
Date: Thursday, April 17, 2025
Ocular Therapeutix to host investor one-on-one meetings
Location: Boston, MA
A live webcast of the Needham presentation can be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (axitinib intravitreal hydrogel, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral hydrogel or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn, or X.
The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
FAQ
When is Ocular Therapeutix (OCUL) presenting at the Needham Healthcare Conference 2025?
Where can investors watch OCUL's Needham Conference presentation?
What investor events is OCUL attending in April 2025?
Who will represent OCUL at the Needham Healthcare Conference 2025?
